Pfizer Attracts Billion In New Investments As It Begins Using mRNA Technology For Other Viruses

Submitted by News Desk on

With the success of the Covid-19 vaccine by Pfizer / BioNTech and Moderna, Pfizer has announced it is beginning to purse new vaccines and other medicines using the successful mRNA vaccine technology that was used to develop the Covid-19 vaccine.  The Wall Street Journal cited an interview with Pfizer CEO Albert Bourla.  Pfizer declined to give details on which viruses or other medicines it was looking to develop.

News of this has attracted billion in new private investment to Pfizer and German drugmaker BioNTech, the company Pfizer partnered with to develop the current Covid-19 vaccine.  The Covid-19 vaccine’s mRNA technology is the first of its kind and was possible after scientist were able to fully sequence the DNA of the coronavirus Covid-19 last year in February.  The mRNA idea sprung from that in March of 2020 when Pfizer put forward a vaccine that was developed specifically from the sequenced DNA of the Covid-19 virus.

Roughly $200 billion in new investments have become available to Pfizer, coming from institutional investors as well as private investments from various banks, lenders and private investment firms from Israel and the United States.

Continued widespread testing and monitoring of the Pfizer and Moderna vaccine show that they are highly effective and very safe.  Pfizer’s vaccine has been tested against the new variants from South Africa, Brazil and the U.K.  In each case, Pfizer’s vaccine preformed well against those variants.